Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06355453 · ClinicalTrials.gov registry record
Evaluation of the Goldcrest Patch Performance
A clinical trial, sponsored by GE Healthcare.
- Completed
- Registry status
- 38
- Enrollment target
NCT06355453: Completed study, sponsored by GE Healthcare.
NCT06355453 is a clinical trial that has completed, run by GE Healthcare. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06355453 has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
The Novii Patch is an accessory to the Novii+ Pod that connects directly to the Novii+ Pod and contains the surface electrodes that attach to the abdomen. The primary objective is to collect Data on Skin Integrity and Patch Adhesion Quality From the Patch After 18 Hours of Wear. The secondary objective is to evaluate fetal monitoring on adult pregnant females greater than 32 weeks gestation and non-pregnant females to collect data on electrical fetal, maternal, and uterine activity.
Primary Outcome
To collect of skin integrity quality from a skin assessment scale the from the patch's after 18-hours of wear.
Interventions
- DEVICE Goldcrest Patch and Three Patch Coupons
- DEVICE Goldcrest Patch and Novii Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2025-03-31 |
What the finished NCT06355453 record still lists
NCT06355453 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Goldcrest Patch and Three Patch Coupons is the first listed.
NCT06355453 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06355453 about?
NCT06355453 is a clinical study titled "Evaluation of the Goldcrest Patch Performance". The Novii Patch is an accessory to the Novii+ Pod that connects directly to the Novii+ Pod and contains the surface electrodes that attach to the abdomen. The primary objective is to collect Data on Skin Integrity and Patch Adhesion Quality From the Patch After 18 Hours of Wear. The secondary objec...
What is the current status of trial NCT06355453?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2024-04-22. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT06355453?
The interventions under investigation include: Goldcrest Patch and Three Patch Coupons (DEVICE), Goldcrest Patch and Novii Patch (DEVICE).
Who is sponsoring clinical trial NCT06355453?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI